Characteristics of long-term gastric cancer survivors ID'd

Characteristics of long-term gastric cancer survivors ID'd
Patients with gastric and gastroesophageal junction cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

(HealthDay)—Patients with gastric and gastroesophageal junction (GEJ) cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

Pamela L. Kunz, M.D., of the Stanford University School of Medicine in California, and colleagues conducted a population-based study involving 47,647 patients diagnosed with gastric or GEJ adenocarcinoma between 1988 and 2005 who were part of the California Cancer Registry, a member of the 's Surveillance, Epidemiology, and End Results program.

Overall, only 20 percent of patients survived at least three years. The researchers found that longer survival correlated with several factors, including earlier stage, surgery, chemotherapy, radiation, intestinal histology, well- or moderately-differentiated tumors, race (Asian/Pacific Islander and Hispanic), gender (female), socioeconomic status (highest quintile), treatment at an , anatomic location (fundus/body/antrum), and hospital size (more than 150 beds). Patients with tumors originating in the fundus/body/antrum had longer median disease-specific survival compared to those with tumors originating in the esophagus/cardia (13.4 versus 10.8 months). Median disease-specific survival was significantly longer for intestinal histology (28.9 months) compared with other (11.0 months) or diffuse histology (10.1 months).

"This large population-based study will serve as a platform for developing future work to better understand factors involved in long-term survivors of , including genetic, genomic, and survivorship studies," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Probability of long-term glioblastoma survival assessed

May 28, 2012

(HealthDay) -- Although the overall mortality rate of glioblastoma is high, compared with patients newly diagnosed with glioblastoma, those who survive two years or more after diagnosis have a favorable conditional ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.